Lipid lowering: an important factor in preventing adriamycin-induced heart failure.

摘要: The contribution of lipid lowering in protection against adriamycin cardiomyopathy achieved by probucol, an antioxidant and a lipid-lowering drug, was assessed comparing its beneficial effects with that lovastatin, another drug no known properties. Adriamycin (cumulative dose, 15 mg/kg body weight) given to rats 6 equal injections (intraperitoneally) over period 2 weeks. Probucol 120 or lovastatin 48 12 before concurrent adriamycin. After 3 weeks post-treatment adriamycin, congestive heart failure, ascites, congested liver, depressed cardiac function were seen. treatment decreased glutathione peroxidase activity increased peroxidation. plasma triglycerides, total cholesterol, high- low-density lipoproteins. Myocardial triglycerides cholesterol also increased. completely prevented the development failure normalized myocardial significantly Lovastatin attenuated but did not prevent cardiomyopathic changes due lipoproteins as well cholesterol. Plasma high-density still high plus group. improved reduced peroxidation whereas had effect on these adriamycin-induced changes. These data suggest is associated deficit lipids. Complete probucol may be unique combination